Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P07204
UPID:
TRBM_HUMAN
Alternative names:
Fetomodulin
Alternative UPACC:
P07204; Q8IV29; Q9UC32
Background:
Thrombomodulin, also known as Fetomodulin, is a pivotal endothelial cell receptor that binds thrombin to form a complex, crucial for converting protein C to its activated form. This activation plays a key role in modulating blood coagulation by reducing thrombin generation through the inactivation of factors Va and VIIIa.
Therapeutic significance:
Given its central role in coagulation and thrombosis, Thrombomodulin is linked to diseases such as Thrombophilia due to thrombomodulin defect and atypical Hemolytic uremic syndrome. These associations underscore the protein's potential as a target for therapeutic interventions aimed at mitigating thrombosis and improving outcomes in related hemostatic disorders.